{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:38:21Z","timestamp":1781649501427,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","award":["14-0365"],"award-info":[{"award-number":["14-0365"]}],"id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Whether they are injected peri- or intraocularly, corticosteroids are still essential tools in the therapeutic arsenal for treating inflammatory macular oedema. A few years ago, however, only triamcinolone acetonide was available to ophthalmologists. While this compound was initially developed for rheumatological or dermatological use, it has been increasingly deployed in ophthalmology, despite still being off-label. In 2011, the system for delivery of dexamethasone from a biodegradable, injectable implant into the vitreous cavity obtained approval for use in inflammatory macular oedema. While the efficacy and safety of triamcinolone in macular oedema, including inflammatory oedema, have already been studied, there are currently no publications on subconjunctival triamcinolone injections, which are simple, effective and well tolerated. To date, the dexamethasone 700\u2009\u03bcg implant has been authorized for the treatment of noninfectious intermediate and posterior uveitis, but there have been no studies to evaluate the efficacy and safety of the different peri- and intraocular strategies, including the treatment of inflammatory macular oedema.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This protocol is therefore designed to compare the efficacy and safety of peri- and intraocular corticosteroid injections in the treatment of inflammatory macular oedema. In this ongoing study, 142 patients will be included, and the oedematous eye will be randomised to treatment with either subconjunctival triamcinolone injection or an intravitreal implant containing 700\u2009\u03bcg dexamethasone. Follow-up is planned for 6\u2009months with monthly visits. Each visit will include visual acuity measurement, a slit lamp examination, fundoscopy, intraocular pressure measurement, laser flare measurement (if available) and spectral domain optical coherence tomography.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The results of this trial will have a real impact on public health if it is shown that a Kenacort retard\u00ae (i.e. triamcinolone) injection costing just \u20ac2.84 and performed in the physician\u2019s office (with no additional overhead costs) is at least as effective as the dexamethasone 700\u2009\u03bcg implant (Ozurdex\u00ae; costing approximately \u20ac960 with the injection performed in a dedicated room), with no increased side effects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02556424\">NCT02556424<\/jats:ext-link>. Registered on 22 September 2015.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13063-020-4066-0","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T17:02:50Z","timestamp":1581354170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Chlo\u00e9","family":"Couret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-483X","authenticated-orcid":false,"given":"Alexandra","family":"Poinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Volteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery-Pierre","family":"Riche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Le Lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Errera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Baillif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence Mathilde","family":"Le Jumeau de Kergaradec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chiffoleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Jobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jaulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Biron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hervouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"4066_CR1","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","volume":"113","author":"CWTA Lardenoye","year":"2006","unstructured":"Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446\u20139.","journal-title":"Ophthalmology"},{"key":"4066_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjo.80.9.844","volume":"80","author":"MS Suttorp-Schulten","year":"1996","unstructured":"Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4066_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","volume":"88","author":"OM Durrani","year":"2004","unstructured":"Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159\u201362.","journal-title":"Br J Ophthalmol"},{"key":"4066_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4066_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/ICU.0b013e3282f03d2e","volume":"18","author":"A Rothova","year":"2007","unstructured":"Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol. 2007;18:487\u201392.","journal-title":"Curr Opin Ophthalmol"},{"key":"4066_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0002-9394(98)00003-8","volume":"125","author":"O Weijtens","year":"1998","unstructured":"Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J, et al. Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol. 1998;125:673\u20139.","journal-title":"Am J Ophthalmol"},{"key":"4066_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/S0161-6420(02)01176-4","volume":"109","author":"O Weijtens","year":"2002","unstructured":"Weijtens O, Schoemaker RC, Romijn FPHTM, Cohen AF, Lentjes EGWM, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109:1887\u201391.","journal-title":"Ophthalmology"},{"key":"4066_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0002-9394(14)70131-X","volume":"123","author":"O Weijtens","year":"1997","unstructured":"Weijtens O, van der Sluijs FA, Schoemaker RC, Lentjes EG, Cohen AF, Romijn FP, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997;123:358\u201363.","journal-title":"Am J Ophthalmol"},{"key":"4066_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0002-9394(99)00129-4","volume":"128","author":"O Weijtens","year":"1999","unstructured":"Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128:192\u20137.","journal-title":"Am J Ophthalmol"},{"key":"4066_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/archopht.1995.01100070041022","volume":"113","author":"PH Kalina","year":"1995","unstructured":"Kalina PH, Erie JC, Rosenbaum L. Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol Chic Ill 1960. 1995;113:867\u20139.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"key":"4066_CR11","unstructured":"Turpin C. Comment manier la corticoth\u00e9rapie locale et g\u00e9n\u00e9rale en cabinet ? R\u00e9al Ophtalmol. 2013;203:36\u201343."},{"key":"4066_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0002-9394(14)73759-6","volume":"120","author":"CJ Helm","year":"1995","unstructured":"Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;120:55\u201364.","journal-title":"Am J Ophthalmol"},{"key":"4066_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/jop.2008.0087","volume":"25","author":"YS Byun","year":"2009","unstructured":"Byun YS, Park Y-H. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2009;25:159\u201362.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"key":"4066_CR14","first-page":"936","volume":"111","author":"T Sakamoto","year":"2007","unstructured":"Sakamoto T, Hida T, Tano Y, Negi A, Takeuchi S, Ishibashi T, et al. Survey of triamcinolone acetonide for ocular diseases in Japan. Nippon Ganka Gakkai Zasshi. 2007;111:936\u201345.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"4066_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/IAE.0b013e318188c814","volume":"29","author":"JA Haller","year":"2009","unstructured":"Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina Phila Pa. 2009;29:46\u201351.","journal-title":"Retina Phila Pa"},{"key":"4066_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12325-011-0019-z","volume":"28","author":"NJS London","year":"2011","unstructured":"London NJS, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28:351\u201366.","journal-title":"Adv Ther"},{"key":"4066_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder C, Belfort R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol Chic Ill 1960. 2011;129:545\u201353.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"key":"4066_CR18","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453\u201360.","journal-title":"Ophthalmology"},{"key":"4066_CR19","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904\u201314.","journal-title":"Ophthalmology"},{"key":"4066_CR20","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1111\/aos.12020","volume":"91","author":"A Bezatis","year":"2013","unstructured":"Bezatis A, Spital G, H\u00f6hn F, Maier M, Clemens CR, Wachtlin J, et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up \u2014 the SOLO study. Acta Ophthalmol. 2013;91:e340\u20137.","journal-title":"Acta Ophthalmol"},{"key":"4066_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5301\/ejo.5000376","volume":"24","author":"G Coscas","year":"2014","unstructured":"Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, et al. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol. 2014;24:1\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"4066_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jfo.2016.11.013","volume":"40","author":"C Carbonni\u00e8re","year":"2017","unstructured":"Carbonni\u00e8re C, Couret C, Bl\u00e9riot A, Lebreton O, Mass\u00e9 H, Le Meur G, et al. Treatment of macular edema: comparison of efficacy and tolerability of subconjunctival triamcinolone injections, sub-tenon\u2019s triamcinolone injections and intravitreal dexamethasone implant. J Fr Ophtalmol. 2017;40:177\u201386.","journal-title":"J Fr Ophtalmol"},{"key":"4066_CR23","doi-asserted-by":"publisher","first-page":"1916.e1","DOI":"10.1016\/j.ophtha.2005.06.009","volume":"112","author":"H Kok","year":"2005","unstructured":"Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112:1916.e1\u20137.","journal-title":"Ophthalmology"},{"key":"4066_CR24","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1167\/iovs.12-10981","volume":"54","author":"S Lightman","year":"2013","unstructured":"Lightman S, Belfort R, Naik RK, Lowder C, Foster CS, Rentz AM, et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci. 2013;54:4864\u201370.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4066_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/2013.jamaophthalmol.102","volume":"131","author":"RK Naik","year":"2013","unstructured":"Naik RK, Rentz AM, Foster CS, Lightman S, Belfort R, Lowder C, et al. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013;131:219\u201325.","journal-title":"JAMA Ophthalmol"},{"key":"4066_CR26","doi-asserted-by":"publisher","first-page":"8939","DOI":"10.1167\/iovs.11-8193","volume":"52","author":"JF Payne","year":"2011","unstructured":"Payne JF, Bruce BB, Lee LBK, Yeh S. Logarithmic transformation of spectral-domain optical coherence tomography data in uveitis-associated macular edema. Invest Ophthalmol Vis Sci. 2011;52:8939\u201343.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4066_CR27","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.ophtha.2009.12.014","volume":"117","author":"FL Ferris","year":"2010","unstructured":"Ferris FL, Miller KM, Glassman AR, Beck RW, Diabetic Retinopathy Clinical Research Network. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology. 2010;117:1512\u20136.","journal-title":"Ophthalmology"},{"key":"4066_CR28","unstructured":"Chevalier J. Mesure de l\u2019utilit\u00e9 attach\u00e9e aux \u00e9tats de sant\u00e9. Valorisation de l\u2019index d\u2019utilit\u00e9 EQ-5D et \u00e9volution de l\u2019\u00e9chelle actuelle en France. France: Paris IX Dauphine; 2010. https:\/\/basepub.dauphine.fr\/bitstream\/handle\/123456789\/5598\/These_JulieChevalier.pdf?sequence=1&isAllowed=y."},{"key":"4066_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10198-011-0351-x","volume":"14","author":"J Chevalier","year":"2013","unstructured":"Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ HEPAC Health Econ Prev Care. 2013;14:57\u201366.","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"key":"4066_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","volume":"14","author":"A Manca","year":"2005","unstructured":"Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14:487\u201396.","journal-title":"Health Econ"},{"key":"4066_CR31","first-page":"345","volume":"53","author":"PJ Karanicolas","year":"2010","unstructured":"Karanicolas PJ, Farrokhyar F, Bhandari M. Practical tips for surgical research: blinding: who, what, when, why, how? Can J Surg J Can Chir. 2010;53:345\u20138.","journal-title":"Can J Surg J Can Chir"},{"key":"4066_CR32","unstructured":"ICMJE | Recommendations | Defining the Role of Authors and Contributors. Available from: http:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html. Cited 28 Sept 2018."},{"key":"4066_CR33","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use Official Journal L 311. 2001. p. 0067\u2013128."},{"key":"4066_CR34","unstructured":"Journal Officiel de la r\u00e9publique Fran\u00e7aise. LOI n\u00b0 2011-2012 du 29 d\u00e9cembre 2011 relative au renforcement de la s\u00e9curit\u00e9 sanitaire du m\u00e9dicament et des produits de sant\u00e9 [Internet]. 2011-2012. 2011. Available from: https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000025053440&categorieLien=id."},{"key":"4066_CR35","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMp1208347","volume":"367","author":"J Emmerich","year":"2012","unstructured":"Emmerich J, Dumarcet N, Lorence A. France\u2019s new framework for regulating off-label drug use. N Engl J Med. 2012;367:1279\u201381.","journal-title":"N Engl J Med"},{"key":"4066_CR36","unstructured":"Department of Health and Human Services. Medicare payments for drugs used to treat wet age-related macular degeneration. Washington, DC: Office of Inspector General; 2012."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4066-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-4066-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4066-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:53:58Z","timestamp":1612835638000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-4066-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4066"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-4066-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"18 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients participating in the study will be given oral and written information about this trial and will sign the informed consent form. An independent ethical review board, the Comit\u00e9 de Protection des Personnes d\u2019Angers, CPP OUEST II, issued a favourable opinion for this clinical trial and gave its informed consent on 24 August 2015.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. This study is considered to be externally funded as MW has been awarded government funding (via a funding body).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}